Phase 3 Juvenile Psoriatic Arthritis Clinical Trials
5 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–5 of 5 trials
Recruiting
Phase 3
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
Active Juvenile Psoriatic Arthritis
Amgen60 enrolled45 locationsNCT04804553
Recruiting
Phase 3
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
Juvenile Psoriatic Arthritis
Bristol-Myers Squibb60 enrolled47 locationsNCT06869551
Recruiting
Phase 3
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Enthesitis Related ArthritisJuvenile Psoriatic Arthritis
UCB Biopharma SRL40 enrolled23 locationsNCT06668181
Recruiting
Phase 3
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Juvenile Psoriatic Arthritis
AbbVie40 enrolled31 locationsNCT06100744
Recruiting
Phase 3
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
Juvenile Psoriatic ArthritisBehçet's Disease
Amgen48 enrolled7 locationsNCT05767047